COVID-19
The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.
Researchers are generating an unprecedented amount of data around COVID-19, with seemingly new and important studies coming out every day. Here’s a look at some of this week’s COVID-19 research news.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
During a Sunday campaign event in Florida, President Donald Trump appeared to hint to the crowd that following the Nov. 3 election, he would terminate the decades-long tenure of Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
BioSpace caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411.
There is an impressive amount of technological ingenuity – mRNA, monoclonal antibodies and more traditional formats – being thrown at the development of a vaccine against COVID-19.
The sound of coughing and gasping breath is coming up fast. A slow look over your shoulder reveals the sweaty, nightmare visage of COVID-19 – or does it?
The U.S. – and global – response to the COVID-19 pandemic has been volatile at best. This is fair, considering that SARS-CoV-2 is a novel virus with a lethality we haven’t seen in more than a century.
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
PRESS RELEASES